Choice of fusion proteins, expression host, and analytics solves difficult-to-produce protein challenges in discovery research

Biotechnol J. 2024 Jan;19(1):e2300162. doi: 10.1002/biot.202300162. Epub 2023 Oct 15.

Abstract

High quality biological reagents are a prerequisite for pharmacological research. Herein a protein production screening approach, including quality assessment methods, for protein-based discovery research is presented. Trends from 2895 expression constructs representing 253 proteins screened in mammalian and bacterial hosts-91% of which are successfully expressed and purified-are discussed. Mammalian expression combined with the use of solubility-promoting fusion proteins is deemed suitable for most targets. Furthermore, cases utilizing stable cell line generation and choice of fusion protein for higher yield and quality of difficult-to-produce proteins (Leucine-rich repeat-containing G-protein coupled receptor 4 (LGR4) and Neurturin) are presented and discussed. In the case of Neurturin, choice of fusion protein impacted the target binding 80-fold. These results highlight the need for exploration of construct designs and careful Quality Control (QC) of difficult-to-produce protein reagents.

Keywords: protein engineering; protein expression; protein purification; recombinant proteins.

MeSH terms

  • Animals
  • Cell Line
  • Mammals*
  • Neurturin*
  • Recombinant Fusion Proteins / genetics

Substances

  • Neurturin
  • Recombinant Fusion Proteins

Grants and funding